https://doi.org/10.48047/AFJBS.6.16.2024.4272-4278

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Association of sleep disturbance with treatment outcome in patients of bipolar affective disorder

Junaid Rasool, Manzoor Ali, Lojain Maqsood, Amjad Iqbal Burq, Mahnoor Irshad, Sadia Islam, Farah Naz Tahir

1. MBBS, FCPS, Assistant Professor of Psychiatry, FMH College of Medicine and Dentistry, Lahore, junaid_sheikh80@yahoo.com
2. MBBS, FCPS, Associate Professor of Psychiatry, Institute of SRA University, Hyderabad, jamalimanzoor@hotmail.com
3. MBBS, Resident Psychiatrist, Sir Ganga Ram Hospital, Lahore, lojainmaq94@gmail.com
4. PhD Scholar, MBBS, DPH, Associate Professor, Islam Medical College, Sialkot, amjadburq@gmail.com
5. FCPS Psychiatry (Training Completed), Services Institute of Medical Sciences, noorirshad1004@gmail.com
6. MPhil Physiology, Associate Professor, Rashid Latif Medical College, sadia.murtaza98@yahoo.com
7. MBBS, MPhil, PhD, Associate Professor, Biochemistry Department, Central Park Medical College, Lahore, tahirnazfarah@gmail.com

Volume 6, Issue 16, Dec 2024

Received: 15 June 2024

Accepted: 21 Nov 2024

Published: 29 Dec 2024

doi:10.48047/AFJBS.6.16.2024.4272-4278

Abstract: Sleep disturbances are prevalent among patients with bipolar affective disorder (BPAD) and may influence treatment outcomes. This study investigates the association between sleep disturbances and treatment efficacy in BPAD patients. The objective was to evaluate the extent to which sleep disturbances impact the therapeutic response, relapse rates, and overall symptom improvement during treatment. Utilizing a cohort of 150 BPAD patients categorized by the presence or absence of clinically significant sleep disturbances, treatment outcomes were assessed over a 12-month period using validated scales. Patients with sleep disturbances exhibited delayed symptom remission (mean reduction in Hamilton Depression Rating Scale: 17.4 ± 3.2 versus 20.1 ± 2.8, $p < 0.01$) and higher relapse rates (35% versus 18%, $p < 0.05$) compared to those without disturbances. These findings suggest that managing sleep disturbances should be a priority in BPAD treatment plans, potentially improving therapeutic outcomes. The study introduces novel insights into the interplay between sleep and mental health in BPAD, underscoring the importance of integrated care approaches. Further exploration of sleep-targeted interventions is warranted.

Keywords: bipolar affective disorder, sleep disturbances, treatment outcomes

Introduction: Bipolar affective disorder (BPAD) is a chronic psychiatric condition characterized by alternating episodes of mania and depression, significantly impairing daily functioning and quality of life. Despite advancements in pharmacological and psychological treatments, outcomes remain suboptimal for a substantial subset of patients. Sleep disturbances, ranging from insomnia to hypersomnia, are increasingly recognized as both symptoms and potential contributors to the pathophysiology of BPAD (Smith et al., 2022). Understanding the bidirectional relationship between sleep disturbances and BPAD treatment outcomes is essential for developing comprehensive care strategies.

Sleep dysregulation in BPAD is multifactorial, involving neurobiological, environmental, and genetic components. Dysfunctions in the circadian system, such as disruptions in melatonin production and altered hypothalamic-pituitary-adrenal (HPA) axis activity, are well-documented contributors (Jones et al., 2023). These disturbances exacerbate mood episodes and hinder treatment efficacy, suggesting a reciprocal interaction between sleep and mood regulation mechanisms.

Recent research highlights the prevalence of sleep disturbances in BPAD, with estimates suggesting that 65% to 90% of patients report sleep-related issues during acute episodes and 30% to 50% during remission phases (Brown et al., 2023). Emerging evidence links sleep disturbances with reduced response rates to mood stabilizers, antipsychotics, and psychotherapy. Such findings underscore the need for an integrated understanding of sleep and treatment outcomes in BPAD.

Despite this recognition, there is limited exploration of sleep-targeted interventions as adjunctive strategies in BPAD management. Interventions such as cognitive behavioral therapy for insomnia (CBT-I) and chronotherapy have shown promise but remain underutilized in clinical practice (Lee et al., 2023). Furthermore, most studies have focused on short-term outcomes, leaving gaps in understanding long-term implications of sleep disturbances.

The current study seeks to address these gaps by investigating the association between sleep disturbances and treatment outcomes in a cohort of BPAD patients. By examining relapse rates, symptom remission timelines, and overall treatment efficacy, this study aims to provide actionable

insights into optimizing BPAD management. Emphasizing the role of sleep as both a therapeutic target and a clinical indicator may pave the way for improved patient outcomes.

Methodology

This prospective cohort study was conducted in FMH College of Medicine and Dentistry enrolling 150 diagnosed BPAD patients aged 18–60 years. Patients were categorized into two groups: those with significant sleep disturbances (n=80) and those without (n=70), based on the Pittsburgh Sleep Quality Index (PSQI; threshold >5 for significant disturbance). Sample size was calculated using Epi Info software, with a 95% confidence level, 80% power, and an assumed 20% difference in treatment outcomes between groups.

Patients with comorbid neurological disorders or substance abuse were excluded. Verbal consent was obtained following ethical guidelines. All participants received standard BPAD treatment, including mood stabilizers, atypical antipsychotics, and adjunctive psychotherapy. Outcomes were measured over 12 months using the Hamilton Depression Rating Scale (HDRS), Young Mania Rating Scale (YMRS), and relapse rates. Statistical analyses employed t-tests and chi-square tests to evaluate group differences, with $p < 0.05$ considered significant.

Results

Table 1: Demographic Data

Variable	Sleep Disturbance (n=80)	No Sleep Disturbance (n=70)	p-value
Age (years)	38.6 ± 9.4	39.1 ± 8.7	0.72
Gender (Male:Female)	42:38	37:33	0.91
Duration of Illness (years)	12.5 ± 4.8	11.8 ± 5.2	0.48

Explanation: No significant differences were observed in demographic characteristics between groups, ensuring comparability.

Table 2: Treatment Outcomes

Outcome Measure	**Sleep Disturbance**	**No Sleep Disturbance**	**p-value**
HDRS Reduction	17.4 ± 3.2	20.1 ± 2.8	<0.01
YMRS Reduction	16.8 ± 2.9	18.6 ± 2.5	0.03
Relapse Rate (%)	35	18	<0.05

Explanation: Patients with sleep disturbances exhibited significantly poorer treatment outcomes across all measures.

Table 3: Adverse Effects and Patient Satisfaction

Parameter	**Sleep Disturbance**	**No Sleep Disturbance**	**p-value**
Adverse Effects (%)	45	33	0.04
Patient Satisfaction Score	6.8 ± 1.2	8.4 ± 1.1	<0.01

Explanation: Sleep disturbances correlated with higher adverse effects and lower patient satisfaction.

Discussion:

The findings of this study underscore the pivotal role of sleep disturbances in influencing treatment outcomes among patients with bipolar affective disorder (BPAD). The significant differences in remission rates, relapse frequencies, and patient satisfaction between patients with and without sleep disturbances provide robust evidence for sleep as a critical therapeutic target in BPAD management. These results align with the growing body of literature emphasizing the interplay between sleep and mood regulation in psychiatric disorders. Sleep and Mood Dysregulation in

BPAD. Sleep disturbances are intrinsic to the pathophysiology of BPAD, often preceding mood episodes and serving as indicators of relapse. Mechanistically, disruptions in the hypothalamic-pituitary-adrenal (HPA) axis, altered circadian rhythms, and dysregulated neurotransmitter systems contribute to sleep impairments and mood instability (Smith et al., 2022). Research highlights that BPAD patients with poor sleep quality exhibit heightened amygdala reactivity, reduced prefrontal regulation, and exacerbated emotional dysregulation, all of which can undermine treatment efficacy (Jones et al., 2023).

Sleep Disturbances and Treatment Outcomes

This study demonstrates that patients with sleep disturbances experience delayed remission and higher relapse rates. These findings align with prior studies suggesting that sleep disturbances impair the efficacy of mood stabilizers, antipsychotics, and psychotherapeutic interventions. For instance, Lee et al. (2023) reported that BPAD patients with insomnia showed attenuated responses to lithium, attributed to disrupted serotonergic signaling. Similarly, cognitive-behavioral therapy for insomnia (CBT-I) has shown efficacy in improving mood stabilization, highlighting the therapeutic potential of addressing sleep (Brown et al., 2023).

Clinical Implications

The significant correlation between sleep disturbances and adverse outcomes suggests that comprehensive treatment strategies for BPAD should incorporate sleep assessments and interventions. Polysomnography, actigraphy, and validated sleep questionnaires can aid in identifying at-risk patients early. Interventions such as CBT-I, bright light therapy, and melatonin agonists have shown promise in enhancing sleep and mood regulation. Incorporating these into standard care protocols could mitigate relapse risks and improve patient satisfaction (Harris et al., 2023).

Limitations and Future Directions

Although this study provides valuable insights, certain limitations warrant consideration. The observational nature precludes causal inferences, and the reliance on self-reported sleep measures may introduce biases. Future studies could employ longitudinal designs with objective sleep metrics to elucidate causal pathways. Additionally, exploring the molecular mechanisms linking

sleep disturbances with mood dysregulation could inform novel therapeutic targets (Williams et al., 2024).

Relevance to Current Research

Emerging studies emphasize the bidirectional relationship between sleep and mood disorders. Findings from this study resonate with recent literature, such as the work of Miller et al. (2022), which highlighted the role of sleep hygiene education in reducing depressive symptoms in BPAD. The consistency across studies reinforces the need to prioritize sleep in clinical practice, with tailored interventions that address individual sleep profiles.

The association between sleep disturbances and adverse outcomes also raises critical questions about the broader implications of untreated sleep issues in BPAD, including impacts on neurocognitive function, physical health, and overall quality of life. As research evolves, integrating multidisciplinary approaches that combine psychiatric, neurological, and sleep medicine expertise could transform BPAD management (Harrison et al., 2023).

In conclusion, this discussion underscores the necessity of addressing sleep disturbances in BPAD to optimize therapeutic outcomes. By bridging gaps in understanding and care, clinicians can enhance remission rates, reduce relapses, and ultimately improve the quality of life for BPAD patients.

Conclusion

This study highlights that sleep disturbances significantly impair treatment outcomes in BPAD patients, manifesting as delayed symptom remission and increased relapse rates. Addressing sleep disturbances as part of an integrated treatment plan could bridge critical gaps in BPAD management, offering avenues for improved therapeutic efficacy and patient satisfaction. Future research should focus on longitudinal assessments and novel interventions targeting sleep dysregulation.

References

Introduction References

1. Smith J, et al. (2022). Sleep disturbances in psychiatric disorders: A focus on bipolar disorder. Journal of Clinical Psychiatry, 83(2), 123-134.
2. Jones L, et al. (2023). Circadian rhythm dysregulation in mood disorders: Implications for treatment. Psychiatry Research, 315, 114728.
3. Brown H, et al. (2023). The role of insomnia in treatment resistance among bipolar patients. Journal of Affective Disorders, 341, 167-175.
4. Lee S, et al. (2023). Cognitive-behavioral therapy for insomnia in bipolar disorder: A systematic review. Sleep Medicine Reviews, 64, 101057.
5. Miller A, et al. (2022). Sleep hygiene education and its impact on mood stabilization in bipolar disorder. Bipolar Disorders, 24(1), 45-53.
6. . Harris K, et al. (2023). Bright light therapy and its efficacy in treating bipolar depression. Current Psychiatry Reports, 25(3), 180-192.
7. Williams D, et al. (2024). Molecular underpinnings of sleep-mood interactions: A focus on neuroinflammation. Neuroscience, 488, 72-85.
8. Harrison M, et al. (2023). Multidisciplinary approaches in managing sleep disturbances in BPAD. Sleep Health, 9(1), 34-47.
9. . Smith J, et al. (2023). Advances in melatonin-based therapies for psychiatric disorders. Frontiers in Psychiatry, 14, 1002648.